Producing 'Human Elements Based Medical Technologies' in Biotech Companies: Some Ethical and Organisational Ingredients for Innovative Cooking. (March 2013)

• Record Type: Journal Article
• Authors: Tournay, Virginie; Rial-Sebbag, Emmanuelle; Bemme, Dörte; Mahalatchimy, Aurélie; Granjou, Céline; Louvel, Séverine; Cambon-Thomsen, Anne
• Other Names: Tournay Virginie guest-editor.; Louvel Séverine guest-editor.; Granjou Céline guest-editor.
• Is Part Of: Science, technology & society. Volume 18:Number 1(2013)
• Page Start: 93
• Page End: 114
• Publication Date: 2013-03
• Subjects: Technology -- Social aspects -- Periodicals; Science -- Social aspects -- Periodicals; 509
• DOI: 10.1177/0971721813484381
• Languages: English
• ISSNs: 0971-7218

Abstract

This article is based on the findings of an EU-funded qualitative research project, entitled 'From GMP to GBP: Fostering good bioethics practices [GBP] among the European biotechnology industry', which seeks to improve the understanding of bioethical issues through the observation of the daily practices in European biotechnology companies and proposes a methodology approaching ethical issues. The comparative study was carried out in biotech companies in France, Italy, Sweden, Hungary and Belgium which develop a wide range of new technologies, all of them involving human materials or where human subjects participate (in clinical trials). Based on our findings in these local settings, we suggest that the notion of bioethics and the way its production is theorised need to be re-conceptualised. We argue that material practices and moral statements are intermingled in inextricable ways that render the formation of bioethical concerns fully dependent on the organisational landscape in which it is embedded. More precisely, the here presented co-production model of moral statements and organisational practices presents a set of common factors that influence how bioethical discourses are shaped, despite the heterogeneity of their epistemic cultures. For example, the procedural design of cell-based-products, the modes of collecting and storing biological specimen, the relationship between patients and companies and technological transfers to emerging countries are defining components that contribute to the shaping process of bioethical concerns. Thus, the path dependency of bioethical concerns relies on an already existing, specific infrastructure and existing relationships within and outside a company rather than on external judgement subsequently applied to its objects, or a collection of processes of reasoning coming from external institutions.